نتایج جستجو برای: cyp3a4 promoter

تعداد نتایج: 92660  

2014
Ryoichi Fujiwara Tomoo Itoh

Cytochrome P450 (CYP) 3A4 is a membrane protein that catalyzes hydroxylation of endogenous and exogenous substrates. Protein-protein interaction is a crucial factor that regulates the function of enzymes. However, protein-protein interactions involving human CYPs have not been fully understood. In this study, extensive protein-protein interactions involving CYP3A4 were determined by a shotgun a...

Journal: :Molecular pharmacology 2012
Dan Li Roger Gaedigk Steven N Hart J Steven Leeder Xiao-bo Zhong

Cytochrome P450 3A4 (CYP3A4) metabolizes more than 50% of prescribed drugs. The expression of CYP3A4 changes during liver development and may be affected by the administration of some drugs. Alternative mRNA transcripts occur in more than 90% of human genes and are frequently observed in cells responding to developmental and environmental signals. Different mRNA transcripts may encode functiona...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1999
P L Paris P A Kupelian J M Hall T L Williams H Levin E A Klein G Casey J S Witte

Prostate cancer incidence, clinical presentation, and mortality rates vary among different ethnic groups. A genetic variant of CYP3A4, a gene involved in the oxidative deactivation of testosterone, has been associated recently with prostate cancer development in Caucasians. To further investigate this variant, we evaluated its genotype frequencies in different ethnic groups and its association ...

2017
Shuaibing Liu Xiangfen Shi Xin Tian Xiaojian Zhang Zhiyong Sun Liyan Miao

Ticagrelor is the first reversible, direct-acting, potent P2Y12 receptor antagonist in management of acute coronary syndromes. It is rapidly absorbed and extensively metabolized. AR-C124910XX, the major active metabolite, antagonizes the P2Y12 receptor at approximately equal potency. The metabolism of ticagrelor to AR-C124910XX involves CYP3A4 and CYP3A5. CYP3A polymorphisms have been well docu...

2014
Gamal T. Ali Nevin M. Al-azhary Doha A. Mokhtar

Cytochrome P450 3A4 (CYP3A4) is the most plentiful cytochrome P450 in adult human liver and small intestine and is responsible for detoxification of more than 50% of drugs in addition to the metabolic deactivation and metabolism of many carcinogens. Polymorphism of CYP3A4-A-290G considered the only allele that appears to stimulate CYP3A4 expression and has been associated with a number of clini...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2007
Su-Jun Lee Sang Seop Lee Hye-Eun Jeong Ji-Hong Shon Ji-Young Ryu Yu Eun Sunwoo Kwang-Hyeon Liu Wonku Kang Young-Ju Park Chi-Mann Shin Jae-Gook Shin

The objective of this study was to identify CYP3A4 variants in Koreans and to characterize their functional consequences in vitro and in vivo. Four single nucleotide polymorphisms were identified in 50 Koreans by direct DNA sequencing. In an additional genotyping using 248 subjects, CYP3A4(*)18 was confirmed as the most frequent coding variant in Koreans at 1.7%, and its frequency was similar t...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2013
Anne M Filppula Mikko Neuvonen Jouko Laitila Pertti J Neuvonen Janne T Backman

Recent data suggest that the role of CYP3A4 in imatinib metabolism is smaller than presumed. This study aimed to evaluate the quantitative importance of different cytochrome P450 (P450) enzymes in imatinib pharmacokinetics. First, the metabolism of imatinib was investigated using recombinant P450 enzymes and human liver microsomes with P450 isoform-selective inhibitors. Thereafter, an in silico...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2016
Mika Nagai Yoshihiro Konno Masahiro Satsukawa Shinji Yamashita Kouichi Yoshinari

Drug-drug interactions (DDIs) via cytochrome P450 (P450) induction are one clinical problem leading to increased risk of adverse effects and the need for dosage adjustments and additional therapeutic monitoring. In silico models for predicting P450 induction are useful for avoiding DDI risk. In this study, we have established regression models for CYP3A4 and CYP2B6 induction in human hepatocyte...

Journal: :The Journal of pharmacology and experimental therapeutics 2001
J M Baron L B Goh D Yao C R Wolf T Friedberg

Some compounds used for phenotyping of cytochrome P450s are substrates of P-glycoprotein (pgp). It is likely that in these cases, the level of pgp modulates the metabolism of in vivo probes. To address this important issue, we have analyzed the effects of pgp on CYP3A4-mediated reactions in two newly established cell lines (3A4/HR/MDR(-) and 3A4/HR/MDR(+)), which express CYP3A4 in the absence a...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2008
S Harmsen A S Koster J H Beijnen J H M Schellens I Meijerman

Since CYP3A4 is responsible for the biotransformation of over 50% of all clinically used drugs, induction results in an increased clearance of many concomitantly administered drugs, thereby decreasing treatment efficacy or, in the case of prodrugs, lead to severe intoxications. CYP3A4 induction is regulated by the pregnane X receptor, constitutive androstane receptor, and vitamin D receptor. Si...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید